| Up
2005P-0167:
REQUIRE CELGENE CORPORATION TO REVISE THE LABELING OF THALOMID CAPSULES
TO STRENGTHEN WARNINGS OF THE POTENTIAL FOR SERIOUS ADVERSE EVENTS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Document #
|
| Received Date
|
| Filed
Date
|
| Submitter Code
|
| Submitter
|
| FR
Date
|
| FR
Page
|
| Comment Date
|
| Files
|
| Remarks
|
|
|
|
|
|
|
| CP1
|
| 05/04/2005
|
| 05/04/2005
|
| State Government
|
| State of Connecticut
|
|
|
|
|
|
|
| TOC
|
|
|
|
|
| Signature:
|
| Richard Blumenthal
|
|
|
|
|
| ACK1
|
| 05/04/2005
|
| 05/04/2005
|
| Federal Government
|
| HFA-305 to the State
of Connecticut
|
|
|
|
|
|
|
| pdf
|
|
|
|
|
|
|
| Signature:
|
| Lyle D. Jaffe
|
|
Top
| Up
Page last updated
May 19, 2005
kk
Dockets Home Page | Dockets
Contacts and Location | Operating
Status | Item
Code Definitions | Federal
Register
FDA Home Page | Search
FDA Site | FDA A-Z Index
| Contact FDA
FDA/Dockets Management |
